{"product_id":"mcrb-ansoff-analysis","title":"(MCRB) Seres Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Seres Therapeutics, Inc. Ansoff Matrix Analysis helps you quickly map growth options across market penetration, market development, product development, and diversification in a concise framework; the page already includes a real preview\/sample so you can assess style and substance before buying. Purchase the full version to get the complete ready-to-use analysis for strategy, investment, or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSER-109 Phase III CDI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSER-109 is Seres Therapeutics, Inc.'s lead existing product for recurrent Clostridioides difficile infection, backed by a completed Phase III program. In ECOSPOR III, recurrence fell to 12.4% with SER-109 vs 39.8% with placebo at 8 weeks, a 68% relative drop. That late-stage proof supports deeper share in a market where repeat CDI is common and costly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNestec Ltd. commercialization leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc.’s licensing and collaboration with Nestec Ltd. is a direct market-penetration lever because it supports market access and commercialization execution for the current product base. The tie-up helped move SER-109, now VOWST, toward launch readiness: FDA approval came on April 26, 2023, and Seres posted $6.8 million of 2024 revenue, showing the product is already in-market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGI and infectious-disease prescriber targeting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeres Therapeutics should target gastroenterology and infectious-disease prescribers who already treat recurrent C. difficile infection, because SER-109 only wins if those specialists switch routine CDI care to it. Recurrent CDI hits about 35% of patients after a first episode, so education on its oral microbiome mechanism and post-antibiotic use is key. In 2025, penetration depends on specialist trust, not new indications, so channel share comes from current CDI treatment lines and referral habits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRecurrent CDI evidence building\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc. can use the Phase III SER-109 package to deepen recurrent CDI adoption in the existing market, not chase a new disease area. ECOSPOR III showed a 12% recurrence rate at week 8 versus 40% with placebo, a strong signal that supports repeat use, referral flow, and guideline trust. The 87% relative risk reduction gives physicians a clear reason to favor SER-109 over older post-antibiotic options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase III data strengthens trust\u003c\/li\u003e\n\u003cli\u003e12% vs 40% recurrence at week 8\u003c\/li\u003e\n\u003cli\u003e87% relative risk reduction\u003c\/li\u003e\n\u003cli\u003eDrives repeat use and referrals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOral microbiome differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSER-109 is an oral microbiome therapy, so it stands apart from standard anti-infective drugs used for CDI. That differentiation matters in market penetration because it gives Seres Therapeutics, Inc. a clear way to win attention inside an entrenched clinician set that treats about 500,000 U.S. CDI cases each year. The goal is to turn modality novelty into routine use by existing CDI prescribers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral microbiome route, not an antibiotic\u003c\/li\u003e\n\u003cli\u003eClear fit for recurrent CDI care\u003c\/li\u003e\n\u003cli\u003eSupports broader clinician adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOWST’s CDI Win Fuels Seres’ Market Penetration Push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for Seres Therapeutics, Inc. centers on VOWST in recurrent CDI, not new disease areas. ECOSPOR III cut 8-week recurrence to 12.4% vs 39.8% for placebo, helping win specialist trust.\u003c\/p\u003e\n\u003cp\u003eFDA approval on Apr. 26, 2023 and $6.8 million of 2024 revenue show the product is already in market. The push is to grow use among gastroenterologists and infectious-disease prescribers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eECOSPOR III recurrence\u003c\/td\u003e\n\u003ctd\u003e12.4% vs 39.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$6.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix overview of Seres Therapeutics, Inc.’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHelps Seres Therapeutics, Inc. quickly spot growth priorities with a clear, easy-to-use Ansoff matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, regulatory, clinical, and financial sources to validate Seres Therapeutics growth paths for swift, traceable Ansoff Matrix decision support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNestec-led geographic reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Nestec Ltd. collaboration gives Seres Therapeutics, Inc. a way to take SER-109 beyond its core U.S. footprint and into licensed markets. That is classic market development: the same approved product, but sold in more geographies through a partner. The deal structure matters more than new R\u0026amp;D, because it can expand reach without rebuilding Seres’ own commercial base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader CDI care settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc. can grow SER-109 in broader CDI care settings by pushing deeper into hospital discharge pathways, infectious disease clinics, and GI referral networks. Recurrent C. difficile still drives about 500,000 U.S. cases a year, so moving the same therapy into more current-care channels expands reach without changing the product. This is market development, not product change, and it fits a well-defined infection market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-enabled market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc. can use partners to widen access to an existing therapy without changing its clinical profile. In 2024, Nestlé Health Science took over VOWST commercialization in the U.S. and Canada, showing Seres can reach a larger provider and pharmacy network through alliance-led distribution. VOWST remains the only FDA-approved oral microbiota therapy, so market development here is about reach, not new claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCDI commercialization beyond Cambridge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc. is based in Cambridge, Massachusetts, but its CDI franchise is a national asset, not a local one. Vowst became the first FDA-approved oral microbiota product for recurrent CDI in 2023, so the same franchise can expand beyond Cambridge through specialty pharmacies, hospital systems, and partner networks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame CDI franchise, wider U.S. reach\u003c\/li\u003e\n\u003cli\u003ePartner-led commercialization lowers local limits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty channel expansion for recurrent CDI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc. can widen recurrent CDI reach by adding referral-heavy specialty channels, especially gastroenterology and infectious disease networks that already manage high-risk patients. Vowst is built for specialist-led adoption, not one direct sales lane; in the phase 3 program, 182 adults were studied and recurrence fell to about 8% versus 47% with placebo.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse referral networks to expand access.\u003c\/li\u003e\n\u003cli\u003eTarget recurrent CDI specialist clinics.\u003c\/li\u003e\n\u003cli\u003eDrive adoption through specialist trust.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVowst Expands Access Through Partners in a Large CDI Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc. uses market development to widen Vowst access through partners and specialist channels, not new products. Nestlé Health Science took U.S. and Canada commercialization in 2024, extending reach across existing CDI networks. Recurrent C. difficile still drives about 500,000 U.S. cases a year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVowst FDA approval\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 patients\u003c\/td\u003e\n\u003ctd\u003e182\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurrence\u003c\/td\u003e\n\u003ctd\u003e8% vs 47%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSeres Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just a professional, structured assessment of Seres Therapeutics’ market penetration, product development, market development, and diversification strategies, with actionable recommendations and editable content unlocked after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSER-155 Phase Ib transplant prophylaxis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSER-155 is Seres Therapeutics’ Phase Ib synthetically cultured bacterial formulation for transplant prophylaxis, aimed at cutting gastrointestinal and bloodstream infections plus graft-versus-host disease risk in high-risk allogeneic stem cell transplant patients. The program is a clear new-product move inside Seres’ microbiome platform, extending its live biotherapeutic work beyond earlier Clostridioides difficile focus. In Ansoff terms, it is product development: a new therapy for an existing transplant-care market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSER-287 Phase Ib ulcerative colitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSER-287 is in Phase Ib for ulcerative colitis, so Seres Therapeutics is still testing the candidate before late-stage proof. In Ansoff terms, this is product development: a new therapy aimed at an existing inflammatory bowel disease market. It expands Seres’ pipeline without changing the core disease area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSER-301 Phase Ib ulcerative colitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSER-301 is in Phase Ib for ulcerative colitis, so Seres Therapeutics is building depth in the same clinical market, not betting on one asset. This broadens product breadth and supports the Ansoff market development play: add more microbiome-based options for the same disease area. Ulcerative colitis affects about 1 million people in the U.S., so even one approved product could address a large need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSER-401 metastatic melanoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSER-401 is Seres Therapeutics, Inc.’s oncology candidate for metastatic melanoma, taking its microbiome platform beyond C. difficile infection into cancer research. In Ansoff Matrix terms, this is a clear product development move: a new product for a new therapeutic use, not an extension of the CDI-focused lead asset. Metastatic melanoma remains a high-need market, so the program widens Seres Therapeutics, Inc.’s pipeline risk and upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSER-401 targets metastatic melanoma\u003c\/li\u003e\n\u003cli\u003eExpands microbiome work into oncology\u003c\/li\u003e\n\u003cli\u003eNew product, not CDI reuse\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSER-262 CDI pipeline asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSER-262 is Seres Therapeutics, Inc. another Clostridioides difficile infection, or CDI, asset, so it extends the same disease focus with a separate program. In Ansoff terms, this is product development: the Company is using its CDI know-how to build a second wave of assets instead of widening into a new market.\u003c\/p\u003e\n\u003cp\u003eThat matters because CDI is a relapse-prone area, and having more than one candidate can spread risk and deepen the pipeline. The value is not just one product; it is a broader CDI franchise that can support future clinical and commercial options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSecond CDI asset, not a new disease area\u003c\/li\u003e\n\u003cli\u003eAdds pipeline depth and option value\u003c\/li\u003e\n\u003cli\u003eFits product-development strategy\u003c\/li\u003e\n\u003cli\u003eSupports a second-wave CDI story\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeres Bets on Breadth: Five Microbiome Assets, One Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeres Therapeutics’ Product Development in Ansoff terms is new microbiome drugs for existing high-need markets: SER-155 for transplant prophylaxis, SER-287 and SER-301 for ulcerative colitis, SER-401 for metastatic melanoma, and SER-262 for CDI. The clearest value is pipeline depth across 5 assets, mostly Phase Ib, which spreads clinical risk while keeping the core platform. One line: it is breadth, not market expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003ePhase\u003c\/th\u003e\n\u003cth\u003eAnsoff fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-155\u003c\/td\u003e\n\u003ctd\u003eTransplant prophylaxis\u003c\/td\u003e\n\u003ctd\u003ePhase Ib\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-287\u003c\/td\u003e\n\u003ctd\u003eUlcerative colitis\u003c\/td\u003e\n\u003ctd\u003ePhase Ib\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-301\u003c\/td\u003e\n\u003ctd\u003eUlcerative colitis\u003c\/td\u003e\n\u003ctd\u003ePhase Ib\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-401\u003c\/td\u003e\n\u003ctd\u003eMetastatic melanoma\u003c\/td\u003e\n\u003ctd\u003ePhase Ib\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-262\u003c\/td\u003e\n\u003ctd\u003eCDI\u003c\/td\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSER-155 transplant market entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSER-155 is a clear diversification move for Seres Therapeutics, Inc., taking the company from recurrent CDI into transplant prophylaxis. It targets 2 new end markets: allogeneic hematopoietic stem cell transplant and solid organ transplant patients. That is a different commercial lane from the CDI franchise, and SER-155 is in Phase 1b, so the addressable market is still being validated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogeneic HSCT infection prevention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogeneic HSCT patients face acute infection risk, and SER-155 is designed to cut gastrointestinal and bloodstream infections in this narrow setting. In a Phase 1b study of 16 patients, Seres Therapeutics, Inc. reported signals that support this transplant-focused use case. That shifts the Company from infectious-disease treatment into transplant-support care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolid organ transplant protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSER-155’s solid organ transplant push is a diversification move: it targets a new patient pool with separate buyers, protocols, and drug-use pathways from recurrent CDI. In transplant care, infection prevention is a high-value need because solid organ transplant recipients can face long-term immunosuppression and frequent prophylaxis use. That gives Seres Therapeutics, Inc. a second clinical market beyond CDI, with a different commercial base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUlcerative colitis franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSER-287 and SER-301 shift Seres Therapeutics, Inc. into ulcerative colitis, a different disease category from CDI. That matters because UC uses different prescribers, longer treatment use, and a much larger market: about 3.2 million adults in the U.S. and Europe live with inflammatory bowel disease, with UC making up roughly half of cases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eNew disease area for the microbiome platform\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eDiversifies beyond CDI prescribers and dynamics\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTargets chronic, repeat-use treatment demand\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMSKCC oncology collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMSKCC collaboration around SER-401 is Seres Therapeutics, Inc.’s clearest diversification move: it shifts the company from infection biology into oncology, specifically metastatic melanoma. That broadens the addressable market beyond microbiome infection therapies and adds a new clinical path with Memorial Sloan Kettering Cancer Center.\u003c\/p\u003e\n\u003cp\u003eSER-401 was tested in a 2020 Phase 1b study in 20 patients with resected, checkpoint-inhibitor-treated metastatic melanoma, so this is still a small early-stage bet. The value is strategic, not near-term revenue, because it opens a second therapeutic lane for Seres.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMoves Seres into oncology\u003c\/li\u003e\n\u003cli\u003eUses MSKCC credibility\u003c\/li\u003e\n\u003cli\u003ePhase 1b: 20 patients\u003c\/li\u003e\n\u003cli\u003eDiversifies from infection focus\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeres Expands Beyond CDI With New Transplant, IBD, and Oncology Bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeres Therapeutics, Inc. uses diversification by pushing SER-155 into transplant prophylaxis and SER-287\/SER-301 into ulcerative colitis, moving beyond recurrent CDI into new buyers, protocols, and markets. SER-155’s Phase 1b study enrolled 16 allogeneic HSCT patients, while SER-401 extended the platform into oncology with 20 metastatic melanoma patients.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-155\u003c\/td\u003e\n\u003ctd\u003eTransplant\u003c\/td\u003e\n\u003ctd\u003ePhase 1b\u003c\/td\u003e\n\u003ctd\u003e16 HSCT patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-287\/SER-301\u003c\/td\u003e\n\u003ctd\u003eUlcerative colitis\u003c\/td\u003e\n\u003ctd\u003eEarly stage\u003c\/td\u003e\n\u003ctd\u003e~3.2M IBD patients in U.S. and Europe\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSER-401\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003ePhase 1b\u003c\/td\u003e\n\u003ctd\u003e20 melanoma patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234627723529,"sku":"mcrb-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mcrb-ansoff-matrix.webp?v=1785724736","url":"https:\/\/dcfanalyst.com\/products\/mcrb-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}